Studies CGRP-targeting migraine preventive medicines in real-world patients
Observes adults with migraine who take CGRP-targeting preventive drugs over 2 years.
Plain-language title generated from the registry record
Registry title: Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
Key facts
- Where
- Albacete, Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Mollet del Vallès, Viladecans, and Zaragoza, SpainSee the 10 sites
Where in Spain
- Hospital General Universitario de AlbaceteAlbacete, SpainTaking people
- Germans Trias I Pujol HospitalBadalona, SpainTaking people
- Vall d'Hebron University HospitalBarcelona, SpainTaking people
- Hospital Universitari de BellvitgeL'Hospitalet de Llobregat, SpainTaking people
- Fundación Jiménez DíazMadrid, SpainTaking people
- Hospital Universitario Gregorio MarañónMadrid, SpainTaking people
- La Paz University HospitalMadrid, SpainTaking people
- Fundació Sanitària MolletMollet del Vallès, SpainNot yet recruiting
- Hospital de ViladecansViladecans, SpainTaking people
- Hospital Clinico Universitario Lozano BlesaZaragoza, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospital Universitari Vall d'Hebron Research Institute
- Trial code
- NCT07159750
- Record updated
- 8 September 2025
- Original description
The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.Read full original descriptionShow less
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.
Inclusion: Migraine diagnosis according to ICHD-III; Prescription of erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant according to prescriptor criteria and reimbursement criteria according to local regulations; Signature of informed consent.
Exclusion: Active severe psychiatric condition or cognitive impairment which may affect the ability to consent patient's participation in the study; Presence of headache different from migraine.